The Patentees contend that, having regard to the basis upon which GenRx has obtained listing under the Pharmaceutical Benefits Scheme, the GenRx products are medicaments for decreasing mortality resulting from congestive heart failure in humans. '  31 DILATREND was first listed in the Schedule of Pharmaceutical Benefits on 1 May 1998. That observation can be made of many of the Claims of the complete specification of the Patent. The publication says:  'The first dose of carvedilol is 3.125 mg. That would trigger a price reduction in the Patentees' products and other drugs within this price reference group.